It showed that T-DXd was superior to the treatment of physician’s choice in patients with metastatic HER2-positive breast cancer previously treated with T-DM1, with a hazard ratio of 0.36 for progression-free survival (PFS) (95% CI 0.28 to 0.45; p < 0.0001) [67]. Here, ERBB2 is linked to breast cancer.